Abstract
The liver is a vital organ with multiple functions and a large regenerative capacity. Tumours of the liver are the second most frequently cause of cancer-related death and develop in chronically inflamed livers. IL-6-type cytokines are mediators of inflammation and almost all members signal via the receptor subunit gp130 and the downstream signalling molecule STAT3. We here summarize current knowledge on how gp130 signalling and STAT3 in tumour cells and cells of the tumour micro-environment drives hepatic tumorigenesis. We furthermore discuss very recent findings describing also anti-tumorigenic roles of gp130/STAT3 and important considerations for therapeutic interventions.
| Original language | English |
|---|---|
| Pages (from-to) | 609-624 |
| Number of pages | 16 |
| Journal | Seminars in Immunopathology |
| Volume | 43 |
| Issue number | 4 |
| DOIs | |
| State | Published - Aug 2021 |
Bibliographical note
Publisher Copyright:© 2021, The Author(s).
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Anti-tumour immunity
- Cholangiocarcinoma (CCA)
- Hepatocellular carcinoma (HCC)
- IL-6
- Inflammation
- STAT3
- Tumour micro-environment
- gp130
Fingerprint
Dive into the research topics of 'The two facets of gp130 signalling in liver tumorigenesis'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver